Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Trajectory of cognitive functions in bipolar disorder: for better or worse?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Incidence of suicidal behaviour and violent crime following antidepressant medication: a Danish cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Response to comment on Osler et al: misinterpretation of pre- and post differences invalidate the authors' conclusion

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  4. Societal costs of Borderline Personality Disorders: a matched-controlled nationwide study of patients and spouses

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Meta-analysis of antidepressant effects of anti-inflammatory drugs-reply

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  1. The Agents Intervening against Delirium in the Intensive Care Unit-Trial (AID-ICU trial):- a detailed statistical analysis plan

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effectiveness of cognitive remediation in the ultra-high risk state for psychosis

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Glucose-dependent Insulinotropic Polypeptide (GIP) reduces bone resorption in patients with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Differential time responses in inflammatory and oxidative stress markers after a marathon: An observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: Schizophrenia is associated with profound cognitive and psychosocial impairments. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used for diabetes and obesity treatment, and animal studies have indicated cognitive-enhancing effects. In this investigator-initiated, double-blind, randomized, placebo-controlled trial, we tested non-metabolic effects of exenatide once-weekly (Bydureon™) in obese, antipsychotic-treated patients with schizohrenia spectrum disorder.

METHOD: Before and after 3 months of exenatide (N = 20) or placebo (N = 20) treatment, patients were assessed with the following: Brief Assessment of Cognition in Schizophrenia (BACS), Rey-Osterreith complex figure test (REY), Short-Form Health Survey (SF-36), Personal and Social Performance Scale (PSP) and the Positive and Negative Syndrome Scale (PANSS). We used BACS composite score as the main outcome measure.

RESULTS: Repeated measures analysis of variance on BACS composite score showed significant effect of 'Time' (P < 0.001), no effect of 'Group' (P = 0.64) and no 'Time*Group' interaction (P = 0.77). For REY, SF-36, PSP and PANSS, only significant 'Time' effects were found.

CONCLUSION: The non-significant results of this first clinical trial exploring non-metabolic effects of a long-acting GLP-1RA in patients with schizophrenia could reflect a general problem of translating cognitive-enhancing effects of GLP-1RAs from animals to humans or be explained by factors specifically related to schizophrenia spectrum patients with obesity such as antipsychotic treatment.

OriginalsprogEngelsk
Artikelnummer1
TidsskriftActa Psychiatrica Scandinavica
Vol/bind136
Udgave nummer1
Sider (fra-til)52-62
Antal sider11
ISSN0001-690X
DOI
StatusUdgivet - jul. 2017

ID: 50119900